Teva Bulks Up Biopharma With $400 Million CoGenesys Acquisition
Teva Pharmaceuticals will acquire the privately held biopharma CoGenesys for $400 million in an effort to strengthen its biogenerics position, the company announced Jan. 22
Teva Pharmaceuticals will acquire the privately held biopharma CoGenesys for $400 million in an effort to strengthen its biogenerics position, the company announced Jan. 22